A new lab assay developed by researchers at Fred Hutch Cancer Center could make diagnosis and treatment of small-cell lung cancer and non-small cell lung cancer easier.

On Monday, Tempus AI Inc. (NASDAQ:TEM) announced the introduction of xM for treatment response monitoring/TRM. This new liquid biopsy assay is designed to detect molecular responses to immune ...

The new assay addresses monitoring needs in prostate cancer treatment, particularly for patients developing resistance to therapy. According to the company, the AR inhibitor market is projected to ...

The data presented also demonstrated how the Oncobiota assay, unlike other liquid biopsy assays for lung cancer, uses microbial signals to achieve histological subtype discrimination in lung ...

Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference ...